Valuation: Repare Therapeutics Inc.

Market Cap 112M 98.08M 90.39M 83.78M 159M 10.64B 162M 1.08B 422M 5.25B 421M 412M 18.15B P/E 2023
-3.28x
P/E 2024 -0.66x
Enterprise Value -38.78M -33.93M -31.27M -28.99M -55.02M -3.68B -55.91M -375M -146M -1.82B -146M -142M -6.28B EV / Sales 2023
1,707,888x
EV / Sales 2024 -1,779,624x
Free-Float
99.77%
Yield 2023 *
-
Yield 2024 -
1 day+0.76%
6 months+3.11%
Current year+1.92%
Current year 2.5
Extreme 2.5
2.65
1 year 1.37
Extreme 1.37
2.66
3 years 0.89
Extreme 0.89
13.85
5 years 0.89
Extreme 0.89
35.75
10 years 0.89
Extreme 0.89
46.44
Manager TitleAgeSince
President - 28/01/2026
Director TitleAgeSince
Director/Board Member - 28/01/2026
Date Insider Type Main position Quantity % Market Cap.
01-28Issuer sale

Chairman

7,500 0.0174%
01-28Issuer sale

Chief Executive Officer

1,167,586 2.7085%
01-28Issuer sale

Controller/Auditor

82,122 0.1905%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-.--%+84.03%-75.05% 114M
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.40%+1.52%+418.46%+620.42% 40.39B
+0.75%+7.38%+27.71%-4.31% 34.38B
-0.85%+7.52%+27.14%+61.64% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
-0.10%+0.37% - - 16.64B
-3.40%+3.14%+71.28%+131.91% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.50%+8.40%+105.72%+105.72% 13.75B
Average +0.23%+3.27%+84.08%+100.57% 24.61B
Weighted average by Cap. +0.09%+4.10%+95.36%+140.62%

Financials

2023 2024
Net sales 51.13 44.75 41.24 38.22 72.56 4.85K 73.73 494.48 192.3 2.4K 191.97 187.81 8.28K 53.48 46.8 43.13 39.98 75.89 5.08K 77.11 517.15 201.11 2.5K 200.77 196.42 8.66K
Net income -93.8M -82.08M -75.65M -70.11M -133M -8.9B -135M -907M -353M -4.39B -352M -345M -15.19B -84.69M -74.11M -68.3M -63.31M -120M -8.04B -122M -819M -318M -3.97B -318M -311M -13.71B
Net Debt -220M -193M -178M -165M -312M -20.9B -318M -2.13B -828M -10.31B -827M -809M -35.65B -151M -132M -122M -113M -214M -14.32B -218M -1.46B -567M -7.07B -566M -554M -24.42B
Logo Repare Therapeutics Inc.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. RPTX Stock